Last €104.29 EUR
Change Today -4.37 / -4.02%
Volume 0.0
UTH On Other Exchanges
As of 3:17 PM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

united therapeutics corp (UTH) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/10/14 - €109.75
52 Week Low
06/18/14 - €62.62
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

united therapeutics corp (UTH) Related Businessweek News

View More BusinessWeek News

united therapeutics corp (UTH) Details

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

706 Employees
Last Reported Date: 02/25/14
Founded in 1996

united therapeutics corp (UTH) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $992.7K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $808.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $543.8K
Executive Vice President of Strategic Plannin...
Total Annual Compensation: $702.9K
Compensation as of Fiscal Year 2013.

united therapeutics corp (UTH) Key Developments

United Therapeutics Corporation Announces Executive Promotions, Effective January 1, 2015

United Therapeutics Corporation announced two senior executive promotions. Senior Executive promotions: the company announced the promotion of Roger Jeffs, Ph.D. to President and Co-Chief Executive Officer and David Zaccardelli, Pharm. D. to Executive Vice President and Chief Operating Officer. In connection with these promotions, Dr. Rothblatt's title will change from Chairman and Chief Executive Officer to Chairman and Co-Chief Executive Officer. As Chairman of the Board and Co-Chief Executive Officer, Dr. Rothblatt will continue to serve as the principal executive officer of the company. These title changes will become effective January 1, 2015. Dr. Jeffs joined United Therapeutics in 1998 and currently serves as the company's President and Chief Operating Officer, a position he has held since 2001. Dr. Zaccardelli currently serves as Chief Manufacturing Officer and EVP, Pharmaceutical Development, a position he has held since 2008.

Katherine J. Klein Joins the United Therapeutics Corporation Board of Directors

United Therapeutics Corporation announced the appointment of Professor Katherine J. Klein, Ph.D., of The Wharton School of the University of Pennsylvania to its Board of Directors as an independent director. The appointment is effective as of November 11, 2014. Professor Klein has served as the Vice Dean of the Wharton Social Impact Initiative since July 2012, and as The Wharton School's Edward H. Bowman Professor of Management since 2005.

United Therapeutics Corporation Announces Unaudited Consolidated Earnings Results for Third Quarter and Nine Months Ended September 30, 2014

United Therapeutics Corporation announced unaudited consolidated earnings results for third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $329,950 million, operating loss of $32,236 million, loss before income taxes of $35,833 million, net loss of $25,237 million or $0.53 per diluted share compared to the total revenues of $302,225 million, operating income of $104,649 million, income before income taxes of $101,179 million, net income of $62,685 million or $1.17 per diluted share for the same quarter a year ago. For the nine months period, the company reported total revenues of $942,156 million, operating income of $360,223 million, income before income taxes of $350,416 million, net income of $224,139 million or $4.12 per diluted share compared to the total revenues of $827,967 million, operating income of $320,990 million, income before income taxes of $310,533 million, net income of $204,874 million or $3.9 per diluted share for the same period a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UTH:GR €104.29 EUR -4.37

UTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.116.60 CHF -2.00
Alexion Pharmaceuticals Inc $184.20 USD +2.24
Celanese Corp $60.83 USD +0.52
Nippon Shinyaku Co Ltd ¥3,900 JPY -20.00
Vertex Pharmaceuticals Inc $117.42 USD +2.27
View Industry Companies

Industry Analysis


Industry Average

Valuation UTH Industry Range
Price/Earnings 36.7x
Price/Sales 5.0x
Price/Book 5.2x
Price/Cash Flow 31.9x
TEV/Sales 4.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNITED THERAPEUTICS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at